What do you think about the use of DTI-MRI for tracking the progress of therapy in Geron’s upcoming Phase I clinical trial? DTI measures (transverse and longitudinal diffusivity) in some rodent models of spinal cord injury have shown correlations with myelination and axonal integrity. If the intraspinally injected oligodendrocyte progenitor cells are indeed remyelinating damaged axons, then perhaps tracking patients with non-invasive DTI-MRI could allow the investigators to better assess the outcomes of their intervention?
Using DTI-MRI in Geron’s Phase I Clinical Trial